| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | VRNA | Ordinary Shares | Award | $0 | +50,000 | +1.9% | $0.000000 | 2,721,480 | 01 Feb 2025 | Direct | F1, F2 |
| transaction | VRNA | Ordinary Shares | Tax liability | $238,082 | -33,240 | -1.2% | $7.16 | 2,688,240 | 03 Feb 2025 | Direct | F1, F3, F4, F5 |
| Id | Content |
|---|---|
| F1 | Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. |
| F2 | Represents an award of Ordinary Shares upon vesting of Performance Restricted Share Units in connection with the Issuer's first commercial sale of ensifentrine. |
| F3 | Represents the number of Ordinary Shares withheld to satisfy the tax withholding obligation in connection with the vesting of certain previously reported Restricted Share Units. |
| F4 | The price reported represents the closing price of the Issuer's ADSs on the Nasdaq Stock Market LLC on January 31, 2025 divided by eight (8). |
| F5 | Consists of (i) 722,488 Ordinary Shares underlying Restricted Share Units, each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer (which are represented by 90,311 ADSs); and (ii) 1,965,752 Ordinary Shares underlying 245,719 ADSs. |